Trial Profile
An Open-label, Single-arm, Phase II, Multicenter Study, to Evaluate the Efficacy of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Dec 2021
Price :
$35
*
At a glance
- Drugs Vemurafenib (Primary)
- Indications Brain metastases; Malignant melanoma
- Focus Therapeutic Use
- Sponsors Roche
- 02 Nov 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 01 Jul 2015 Planned End Date changed from 1 Oct 2015 to 1 Jul 2015 as reported by ClinicalTrials.gov record.
- 01 Jul 2015 Planned primary completion date changed from 1 Oct 2015 to 1 Jul 2015 as reported by ClinicalTrials.gov record.